Depth of weight loss drug pipeline will support growth even as cost lowers, says StemPoint’s Ross

Michelle Ross, StemPoint Capital CIO and Novo Nordisk shareholder, joins CNBC’s ‘Closing Bell’ to discuss the criticism Novo has faced around high drug prices, the potential earnings impact if prices come down, and more.